Filana Therapeutics, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
Filana Therapeutics, Inc. (FLNA) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $15.01 per share as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2026-03-12
- 2025-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $15.01.
- 2024-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $20.15.
- 2023-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $15.13.
- 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $12.13.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $15.01 10-K · filed 2026-03-12 |
| 2024-12-31 | $20.15 10-K · filed 2025-03-03 |
| 2023-12-31 | $15.13 10-K · filed 2024-02-28 |
| 2022-12-31 | $12.13 10-K · filed 2023-02-28 |
| 2021-12-31 | $11.56 10-K · filed 2022-03-01 |
| 2020-12-31 | $11.30 10-K · filed 2021-03-23 |
| 2019-12-31 | $12.27 10-K · filed 2020-03-26 |
| 2018-12-31 | $14.14 10-K · filed 2019-03-29 |
| 2017-12-31 | $16.74 10-K · filed 2018-02-06 |
| 2016-12-31 | $3.60 10-K · filed 2017-03-07 |
| 2015-12-31 | $3.75 10-K · filed 2016-03-03 |
| 2014-12-31 | $3.92 10-K · filed 2015-02-18 |
| 2013-12-31 | $4.06 10-K · filed 2014-02-05 |
| 2012-12-31 | $4.27 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |